3 Reasons Exelixis Stock Could Deliver Market‑Beating Returns Over the Next Decade
The Motley Fool
by newsfeedback@fool.com (James Halley)February 28, 2026
The U.S.-based biotech specializes in treating cancers with small molecules, antibody-drug conjugates, and other biotherapeutics.
Verticals
financeinvesting
Originally published on The Motley Fool on 2/28/2026